loading...| Preferred Name |
Alogliptin |
|
| Synonyms |
|
|
| Definitions |
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C76906 |
|
| CAS_Registry |
850649-61-5 |
|
| Chemical_Formula |
C18H21N5O2 |
|
| code |
C76906 |
|
| Contributing_Source |
FDA |
|
| definition |
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. |
|
| FDA_UNII_Code |
JHC049LO86 |
|
| Has_Salt_Form | ||
| in_subset | ||
| label |
Alogliptin |
|
| Legacy Concept Name |
Alogliptin |
|
| NCI_Drug_Dictionary_ID |
733686 |
|
| PDQ_Closed_Trial_Search_ID |
733686 |
|
| PDQ_Open_Trial_Search_ID |
733686 |
|
| Preferred_Name |
Alogliptin |
|
| prefixIRI |
NCIT:C76906 |
|
| prefLabel |
Alogliptin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1958126 |
|
| subClassOf |